License Agreements - Narrative (Details) $ in Thousands							1 Months Ended			3 Months Ended			4 Months Ended	12 Months Ended
		Dec. 02, 2025 USD ($)	Nov. 05, 2025 USD ($)	Sep. 26, 2025 USD ($)	Apr. 28, 2025 USD ($)	Mar. 18, 2025 USD ($)	Feb. 28, 2026 USD ($)	Dec. 31, 2025 USD ($)	Oct. 31, 2025 USD ($)	Mar. 31, 2027 USD ($)	Mar. 31, 2026 USD ($)	Mar. 31, 2025 USD ($)	Mar. 31, 2026 USD ($)	Mar. 31, 2026 USD ($) vote employee	Dec. 31, 2026 shares	Mar. 26, 2026 shares
Asset Acquisition [Line Items]
Deferred revenue, current								$ 4,156			$ 3,117		$ 3,117	$ 3,117
Purchase of research and development license											(8,000)	$ 0
Research and development	[1]										17,903	$ 10,627
Prepaid expenses and other current assets								5,463			6,400		6,400	$ 6,400
Paragon Option Agreements | Parascent Warrant
Asset Acquisition [Line Items]
Warrants, exercisable (in shares) | shares																34,566
Paragon Option Agreements | Forecast | Parascent Warrant
Asset Acquisition [Line Items]
Warrants, exercisable (in shares) | shares															402,731
License Agreement Terms | Paragon Option Agreements
Asset Acquisition [Line Items]
Number of employees overseeing and coordinating the project | employee														2
Paragon Therapeutics | Paragon Option Agreements
Asset Acquisition [Line Items]
Accounts payable and other current liabilities								100			$ 0		0	$ 0
Percent of outstanding shares											1.00%	1.00%
Paragon Therapeutics | License Agreement Terms | Paragon Option Agreements
Asset Acquisition [Line Items]
Number of employees overseeing and coordinating the project | employee														2
Number of votes | vote														1
Option agreement termination period, maximum contractual period														30 days
Research and development											$ 2,500	$ 8,015
Paragon Therapeutics | License Agreement Terms | CR-001 | Paragon Option Agreements
Asset Acquisition [Line Items]
Non-refundable milestone payments						$ 22,000
Milestone payment					$ 3,000		$ 2,500
Restriction period														5 years
Percent reduction to royalty payment due to invalid patent														30.00%
Termination period due to breach of contract														60 days
Sublicense agreement period														30 days
Paragon Therapeutics | License Agreement Terms | CR-002 | Paragon Option Agreements
Asset Acquisition [Line Items]
Non-refundable milestone payments				$ 46,000
Milestone payment			$ 5,000						$ 5,000
Percent reduction to royalty payment due to invalid patent														30.00%
Termination period due to breach of contract														60 days
Sublicense agreement period														30 days
Kelun-Biotech | License Agreement Terms | CR-001 | Collaborative Arrangement
Asset Acquisition [Line Items]
Deferred revenue		$ 20,000									20,000		20,000	$ 20,000
Consideration transfer, period		30 days
Development milestone payments		$ 30,000											30,000
Contract with customer, liability											15,000		15,000	15,000
Contract with customer, refund liability											5,000		5,000	5,000
Deferred revenue, current								4,200			3,100		3,100	3,100
Kelun-Biotech | License Agreement Terms | CR-001 | Collaborative Arrangement | License
Asset Acquisition [Line Items]
Contract with customer, liability								10,800			1,000		1,000	1,000
Contract with customer, liability, revenue recognized											1,000
Kelun-Biotech | License Agreement Terms | CR-001 | Forecast | Collaborative Arrangement
Asset Acquisition [Line Items]
Combination study approval payment										$ 5,000
Kelun-Biotech | License Agreement Terms | SKB105
Asset Acquisition [Line Items]
Consideration transferred		80,000						$ 80,000
Development milestone payment		345,000
Sale based milestone payment		$ 902,500
Mid-single digits to low-double digits royalty payment, period		18 months
Low-single digits to low-double digits royalty payment, period		24 months
Prepaid expenses and other current assets											$ 1,800		$ 1,800	$ 1,800

[1] Includes related party amount of $2,923 and $8,777 for the three months ended March 31, 2026 and March 31, 2025, respectively.